Clinical experience: Outcomes of mesenchymal stem cell transplantation in five stroke patients

Author:

Ercelen Nesrin,Karasu Nilgun,Kahyaoglu Bulent,Cerezci Onder,Akduman Rana Cagla,Ercelen Defne,Erturk Gizem,Gulay Gokay,Alpaydin Nagihan,Boyraz Gizem,Monteleone Berrin,Kural Zekiye,Silek Hakan,Temur Sibel,Bingol Canan Aykut

Abstract

Stem cell therapy, which has promising results in acute disorders such as stroke, supports treatment by providing rehabilitation in the chronic stage patients. In acute stroke, thrombolytic medical treatment protocols are clearly defined in neurologic emergencies, but in neurologic patients who miss the “thrombolytic treatment intervention window,” or in cases of hypoxic-ischemic encephalopathy, our hands are tied, and we are still unfortunately faced with hopeless clinical implementations. We consider mesenchymal stem cell therapy a viable option in these cases. In recent years, novel research has focused on neuro-stimulants and supportive and combined therapies for stroke. Currently, available treatment options are limited, and only certain patients are eligible for acute treatment. In the scope of our experience, five stroke patients were evaluated in this study, who was treated with a single dose of 1–2 × 106 cells/kg allogenic umbilical cord-mesenchymal stem cells (UC-MSCs) with the official confirmation of the Turkish Ministry of Health Stem Cell Commission. The patients were followed up for 12 months, and clinical outcomes are recorded. NIH Stroke Scale/Scores (NIHSS) decreased significantly (p = 0.0310), and the Rivermead Assessment Scale (RMA) increased significantly (p = 0.0234) for all patients at the end of the follow-up. All the patients were followed up for 1 year within a rehabilitation program. Major clinical outcome improvements were observed in the overall clinical conditions of the UC-MSC treatment patients. We observed improvement in the patients’ upper extremity and muscle strength, spasticity, and fine motor functions. Considering recent studies in the literature together with our results, allogenic stem cell therapies are introduced as promising novel therapies in terms of their encouraging effects on physiological motor outcomes.

Publisher

Frontiers Media SA

Subject

General Medicine

Reference61 articles.

1. Chapter 10 : Cerebrovascular Disease : Ischemic Stroke & Transient Ischemic Attack.;Willey;CURRENT diagnosis & treatment: neurology.,2019

2. Incidence of stroke and ischemic stroke subtypes: a community-based study in brno, czech republic.;Sedova;Cerebrovasc Dis.,2021

3. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase i safety study.;Laskowitz;Stem Cells Transl Med.,2018

4. Pathophysiology and treatment of stroke: present status and future perspectives.;Kuriakose;Int J Mol Sci.,2020

5. Global stroke statistics 2019.;Kim;Int J Stroke.,2020

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3